Intensive Care News and Research

RSS

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009

Biochemists are developing a new system to better understand antibiotic resistance

Rice University biochemists are developing a system of "evolutionary forecasting" to better understand the mechanisms of antibiotic resistance.

22 Sep 2009

Children’s Health Network acquired by MEDNAX

MEDNAX, Inc. (NYSE: MD) has completed the acquisition of Children’s Health Network (CHN), a physician group practice that provides a variety of inpatient pediatric physician services at 11 hospitals in four states.

21 Sep 2009

Community events conducted by the Hospital at Craig Ranch

...

21 Sep 2009

March of Dimes to re-launch Healthy Baby program for military families

Military moms whose babies were born too soon or too sick were treated to a very special baby shower today at the Portsmouth Naval Medical Center Neonatal Intensive Care Unit (NICU) courtesy of the March of Dimes and Operation Shower.

21 Sep 2009

Book on the effects of antibiotic-resistant microbes

In RISING PLAGUE: THE GLOBAL THREAT FROM DEADLY BACTERIA AND OUR DWINDLING ARSENAL TO FIGHT THEM (Prometheus Books, $26), Dr. Brad Spellberg-an infectious diseases specialist and member of a national task force charged with attacking antibiotic resistant infections-tells the story of this potentially grave public health crisis.

18 Sep 2009

Vitamin K prevents age-related conditions

An important analysis conducted by Children's Hospital Oakland Research Institute scientists suggests the importance of ensuring optimal dietary intakes of vitamin K to prevent age-related conditions such as bone fragility, arterial and kidney calcification, cardiovascular disease, and possibly cancer. Vitamin K is concentrated in dark green plants such as spinach or Swiss chard, and is either not present or present in only small amounts in most multivitamin pills.

18 Sep 2009

Nuveta closes Series A seed financing round for in vitro fertilization research

Nuveta, Inc., a privately held medical device company and global leader in basic in vitro fertilization (IVF) research, announced today that it has closed a Series A seed financing round, solely funded by Vivo Ventures.

17 Sep 2009

Checklists for improved patient safety

A new report, involving the University of Leicester, has called for greater understanding of how checklists can be used to improve safety. The report has been described as "counter-revolutionary" and providing a "a long overdue and desperately needed reality check for checklists in medicine" by Faculty of 1000 Medicine.

16 Sep 2009

Black patients less likely to survive cardiac arrests in hospitals

Black patients have lower rates of successful resuscitation and are less likely to survive an in-hospital cardiac arrest compared to white patients, according to a study in the Sept. 16 issue of the Journal of the American Medical Association.

16 Sep 2009

Kaiser Permanente launches new state-of-the-art hospital in Downey

Kaiser Permanente has opened a new state-of-the-art 352-bed hospital in Downey, which will provide high-quality, personal, and affordable healthcare in Southeast Los Angeles County for many years into the future.

16 Sep 2009

Oil-and-water-based nanoemulsion could be more effective for treating burns

Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies.

15 Sep 2009

Phase IIa trial results of panobacumab released

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates.

14 Sep 2009

FAB Pharma to develop new class of anti-MRSA drugs

FAB Pharma today announced the completion of a €2.3 million round of series A funding led by CDC innovation and co-led by Bioam Gestion.

14 Sep 2009

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

11 Sep 2009

Doctor examines the link between Guillain-Barr- syndrome and H1N1 vaccination

A doctor who developed Guillain-Barr- syndrome will consider having the swine flu jab when she returns to work this autumn, despite claims that the vaccine is linked to an increased risk of the disease. Laura Claire Price, a specialist in respiratory and intensive care medicine, examines the reasons why the vaccine might cause the syndrome, reviews the current evidence, and concludes that she will consider having the jab when it becomes available.

11 Sep 2009

The first CardioGraft patch with MatrACELL technology implant performed

LifeNet Health, a leading allograft bio-implant company, announces the first implant of a CardioGraft(TM) allograft cardiac patch product with MatrACELL(TM)( )decellularization technology. The surgery was performed at Children's Mercy Hospital in Kansas City, Mo by Gary K. Lofland, MD, FACS, Section Chief, Cardiovascular Surgery at Children's Mercy Hospital in Kansas City, Mo, The Joseph Boon Gregg/Missouri Endowed Chair in Pediatric Cardiac Surgery, Professor of Surgery, UMKC.

10 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Top 10 U.S.hospitals prefer Arctic Sun temperature management system

The number of Arctic Sun(R) users among hospitals ranked top 20 jumped to 90 percent this year from 72 percent last year, Medivance announced today. All top 10 "best hospitals" prefer the ease and safety of its advanced non-invasive method for rapid, controlled temperature reduction followed by slow rewarming.

9 Sep 2009